Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lioe-Fee de Geus-Oei, MD PhD
With
Amsterdam UMC, location VUmc
Centre for Human Drug Research, Netherlands
The Netherlands Cancer Institute
Age
30–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with radiologically FIGO stage IIIB/IIIC EOC based on the conventional CT scan who are:
scheduled to undergo primary cytoreductive surgery and
1. in whom EOC is histologically proven, or
2. in whom EOC is cytologically suspected and a serum CA125/CEA ratio \> 25 is found
or
treated with neoadjuvant chemotherapy (NACT) and are scheduled to undergo interval cytoreductive surgery and
1. in whom EOC is histologically proven, or
2. in whom EOC is cytologically suspected and a serum CA125/CEA ratio \> 25 was found before NACT
3. and with radiologically FIGO stage IIIB/IIIC EOC based on the response evaluation CT scan after NACT
You may not be if
1. Women younger than 30 years of age (in accordance with the guidelines of the Netherlands Commission on Radiation Dosimetry \[23\], as the total radiation dose will be 7.2 mSv)
2. Patients who previously underwent primary laparotomy and in whom complete or optimal cytoreduction was not considered feasible.
3. Contraindication for PET (pregnancy, lactating or severe claustrophobia)
5. Impaired renal function (defined as eGFR \< 50 mL/1.73 m2)
6. Impaired liver function (ALT, AST or total bilirubin \> 3x upper limit of normal)
7. Clinically significant abnormalities on ECG and/or clinically laboratory test
8. Inability to tolerate lying supine for the duration of a PET/CT examination (\~110 minutes)
9. Patients with concomitant malignancy (except basal cell carcinoma of the skin) or any condition that in the opinion of the investigators could potentially jeopardize the health status of the patient
10. Patients not able to comply with the study procedures
11. Patients who did not give informed consent
Clareo Health | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer
